Value-Added Applications for Hemicellulose and Pharmaceutical Development
First written in FY2019. 10 of 14 entries say "Advanced", first in FY2020-Q1. Latest entry: 2026-09-19.
No other company in this theme has enough history to compare yet.
- 2026-09-19AdvancedGovernance
「Oji Pharma’s business model」
For wood-derived pharmaceuticals, the company has presented a “circular healthcare model” spanning veterinary medicine through human medical security, with a target of annual sales exceeding ¥10 billion in the 2030s. - FY2026AdvancedAnnual report
「For human medicines, the Company obtained domestic marketing approval in February 2026 for a generic prescription drug to treat homocystinuria, a rare disease. In March of the same year, it submitted a clinical trial notification to the Pharmaceuticals and Medical Devices Agency (PMDA) for OJI-220, which is being developed to prevent blood coagulation during the use of extracorporeal circulation equipment for hemodialysis, in order to begin a Phase I clinical trial.」
For pharmaceuticals derived from wood components, progress has been made through the acquisition of marketing approval for a generic human medicine and the submission to PMDA in preparation for a Phase I clinical trial of OJI-220. The Company has also invested in LTLファーマ. - 2026-05-15AdvancedResults briefing materials
「Accelerating initiatives to launch Oji Pharma’s pharmaceutical business」
For pharmaceuticals derived from woody components, the company disclosed the acquisition of shares in LTL Pharma, preparations for domestic Phase I clinical trials, and the launch of administration trials for a veterinary arthritis treatment. - FY2026-H1AdvancedAnnual report
「王子ファーマ is currently pursuing approval for a veterinary arthritis treatment in parallel with R&D on human medicines. In September 2025, it obtained approval in Australia for the manufacture and export of active pharmaceutical ingredients for veterinary medicines.」
For pharmaceuticals derived from wood components, 王子ファーマ obtained approval in Australia in September 2025 to manufacture and export active pharmaceutical ingredients for veterinary medicines, advancing commercialization. - FY2025-H1AdvancedAnnual report
「The Company is developing pharmaceuticals that use major components of wood and can avoid issues associated with reliance on animal-derived materials. In July 2024, 王子ファーマ obtained Class 1 and Class 2 marketing authorization licenses for pharmaceutical products.」
The commercialization of pharmaceuticals derived from wood components has progressed to the stage at which 王子ファーマ obtained Class 1 and Class 2 marketing authorization licenses for pharmaceutical products. - FY2023-Q1AdvancedAnnual report
「王子ファーマ株式会社 is developing sulfated hemicellulose, obtained through the chemical modification of hemicellulose, a component of wood, as a pharmaceutical product and is pursuing a priority application for a veterinary arthritis treatment.」
Development of sulfated hemicellulose as a pharmaceutical product has progressed to the priority application stage for a veterinary arthritis treatment. - FY2022-Q3RestatedAnnual report
「For hemicellulose, a wood-derived component, 王子ファーマ株式会社 is developing chemically synthesized sulfated hemicellulose as a pharmaceutical product. The Company has also invested in 株式会社レクメド, which is likewise developing pharmaceuticals derived from wood, and is conducting joint development.」
The Company continues to develop hemicellulose as a pharmaceutical product, pursue development through 王子ファーマ, and conduct joint development with レクメド. - FY2022-Q1AdvancedAnnual report
「For hemicellulose derived from wood resources, 王子ファーマ株式会社 is developing chemically synthesized sulfated hemicellulose as a pharmaceutical product. The Company has also invested in 株式会社レクメド, which is likewise developing pharmaceuticals derived from wood resources, and is conducting joint development.」
The investment in レクメド has progressed from the decision stage reported previously to implementation, and joint development of pharmaceuticals derived from wood resources is under way. - FY2021-Q3AdvancedAnnual report
「For hemicellulose, one of the components of wood, hydrolyzed xylan extracted and purified using the Group's proprietary technologies is used as a cosmetic ingredient. To further increase the value of hemicellulose, the Company established 王子ファーマ株式会社 in April 2020 to develop chemically synthesized sulfated hemicellulose as a pharmaceutical product. In November 2020, the Company also decided to invest in and jointly develop pharmaceuticals with 株式会社レクメド, which is developing pharmaceuticals based on sodium pentosan polysulfate, another wood-derived component. Going forward, the Group will continue to promote collaboration with universities and pharmaceutical companies and advance R&D on pharmaceuticals derived from wood resources.」
Following the establishment of 王子ファーマ, the Company decided in November 2020 to invest in レクメド and conduct joint development, giving concrete form to the R&D and commercialization of pharmaceuticals derived from wood components. - FY2021-Q1RestatedAnnual report
「For hemicellulose, one of the components of wood, hydrolyzed xylan extracted and purified using the Group's proprietary technologies is used as a cosmetic ingredient. In addition, to further increase the value of hemicellulose, the Group is developing chemically synthesized sulfated hemicellulose as a pharmaceutical product. To accelerate efforts to enter the pharmaceutical business, the Company established 王子ファーマ株式会社 in April 2020 and is promoting collaboration with universities and pharmaceutical companies.」
The Company continues to use hemicellulose as a cosmetic ingredient, develop pharmaceutical products, and promote commercialization through 王子ファーマ. - FY2020AdvancedAnnual report
「To accelerate efforts to enter the pharmaceutical business, the Company established 王子ファーマ株式会社 in April 2020 and is promoting collaboration with universities and pharmaceutical companies.」
Progress has been made from converting hemicellulose into cosmetic ingredients and developing active pharmaceutical ingredients to establishing 王子ファーマ in April 2020 and promoting collaboration with universities and pharmaceutical companies. - FY2020-Q3RestatedAnnual report
「The Group is also pursuing the effective use of hemicellulose, one of the components of wood, by applying its proprietary technologies. Hemicellulose has already been adopted in cosmetics, and development is under way toward its practical application as an active pharmaceutical ingredient. In addition, the Group established a research organization with Hokkaido University in the life sciences field in April 2019 to further strengthen efforts toward practical applications.」
The Company continues to use hemicellulose in cosmetics, develop it toward practical application as an active pharmaceutical ingredient, and operate the research organization with Hokkaido University. - FY2020-Q1AdvancedAnnual report
「The Group is also pursuing the effective use of hemicellulose, one of the components of wood, by applying its proprietary technologies. Hemicellulose has already been adopted in cosmetics, and development is under way toward its practical application as an active pharmaceutical ingredient. In addition, the Group established a research organization with Hokkaido University in the life sciences field to further strengthen efforts toward practical applications in pharmaceuticals and other products.」
Following the adoption of hemicellulose in cosmetics, development toward its practical application as an active pharmaceutical ingredient has progressed, as has the establishment of a research organization with Hokkaido University. - FY2019First statedAnnual report
「The Group has also developed a proprietary technology that enables hemicellulose, a major component of wood, to be converted into high-value-added products. Highly purified hemicellulose is incorporated as a raw material in cosmetics and is already sold nationwide. Sulfated hemicellulose (PPS), produced by purifying and chemically synthesizing hemicellulose, is expected to be developed as an active pharmaceutical ingredient for veterinary and human medicines.」
The Company recorded the nationwide sale of hemicellulose as a cosmetic ingredient and the development of sulfated hemicellulose (PPS) for veterinary and human medicines as new business and R&D themes.